Please assess the completion status of the following clinical trial:

Trial Title: 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Criteria:~* Not pregnant or nursing~* Histopathologically confirmed diagnosis of 1 of the following:~  * Myeloproliferative disorders (MPDs) in aggressive phase or transformation~ * CML in accelerated phase or blast crisis~ * Chronic myelomonocytic leukemia in aggressive phase (5-19% bone marrow blasts) or transformation (\> 20% bone marrow blasts)~* Myeloproliferative disorders (MPDs) in aggressive phase or transformation, including the following:~  * Polycythemia vera (PV)~ * Essential thrombocythemia (ET)~ * Myelofibrosis with myeloid metaplasia~ * Hypereosinophilic syndrome~ * Atypical (Philadelphia chromosome negative) chronic myelogenous leukemia (Ph- CML)~* Patients with aggressive phase MPD (PV, ET, or Ph- CML) must meet ≥ 1 of the following criteria:~  * Marrow blasts \> 5%~ * Peripheral blood blasts plus progranulocytes \> 10%~ * New onset or increasing myelofibrosis~ * New onset or \> 25% increase in hepatomegaly or splenomegaly~ * New onset constitutional symptoms (fever, weight loss, splenic pain, bone pain)~* Multilineage bone marrow failure~* Ineligible for established curative regimens, including stem cell transplantation~* ECOG performance status 0-2~* Negative pregnancy test~* Fertile patients must use effective contraception~* No chronic toxicity from prior chemotherapy \> grade 1~* No history of severe coronary artery disease~* Creatinine normal OR creatinine clearance \>= 60 mL/min~* AST and ALT =\< 2.5 times normal~* Bilirubin =\< 2.0 mg/dL unless due to leukemia, Gilbert's syndrome, or hemolysis~* No arrhythmias (other than atrial flutter or fibrillation) requiring medication~* No uncontrolled congestive heart failure~* No dyspnea at rest or with minimal exertion~* No severe pulmonary disease requiring supplemental oxygen~* No history of allergic reactions attributed to compounds of similar chemical or biological composition to 3-AP (Triapine®) and/or fludarabine phosphate~* No other life-threatening illness~* No history of mental deficits and/or psychiatric illness that would preclude study compliance~* No more than 4 prior induction regimens (3 cytotoxic chemotherapy regimens)~* At least 3 weeks since prior myelosuppressive cytotoxic agents (6 weeks for mitomycin C or nitrosoureas) and recovered~* At least 1 week since prior nonmyelosuppressive treatment~* At least 48 hours since prior noncytotoxic agents for peripheral blood leukemic cell count control, including but not limited to the following:~  * Hydroxyurea~ * Imatinib mesylate~ * Interferon~ * Mercaptopurine~ * Cyclophosphamide~* At least 2 weeks since prior and no concurrent radiotherapy to treat cancer~* At least 1 week since prior biologic therapy, including hematopoietic growth factors (e.g., epoetin alfa, darbepoetin alfa, filgrastim \[G-CSF\], sargramostim \[GM-CSF\], interleukin-3, or interleukin-11)~* No other concurrent chemotherapy to treat cancer~* No concurrent immunotherapy to treat cancer~* No known glucose-6-phosphate dehydrogenase \[G6PD) deficiency (G6PD screening required for high-risk groups (i.e., patients of African, Asian, or Mediterranean origin/ancestry)\]~* No active heart disease~* No concurrent myeloid growth factors~* No active uncontrolled infection (Infections under active treatment and controlled with antibiotics are allowed)~* No chronic hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).